The Survival Function of the Bcr-Abl Oncogene Is Mediated by Bad-Dependent and -Independent Pathways: Roles for Phosphatidylinositol 3-Kinase and Raf

REFERENCES

• Afar, D. E. H., Goga, A., McLaughlin, J., Witte, O., and Sawyers, C. L.. 1994. Differential complementation of Bcr-Abl point mutants with c-Myc. Science 264:424–426
   PubMed Web of Science ®Google Scholar
• Bedi, A., Barber, J. P., Bedi, G. C., el-Deiry, W. S., Sidransky, D., Vala, M. S., Akhtar, A. J., Hilton, J., and Jones, R. J.. 1995. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86:1148–1158
   PubMed Web of Science ®Google Scholar
• Bedi, A., Zehnbauer, B. A., Barber, J. P., Sharkis, S. J., and Jones, R. J.. 1994. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83:2038–2044
   PubMed Web of Science ®Google Scholar
• Benito, A., Silva, M., Grillot, D., Nunez, G., and Fernandez-Luna, J. L.. 1996. Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-XL. Blood 87:3837–3843
   PubMed Web of Science ®Google Scholar
• Carlesso, N., Frank, D. A., and Griffin, J. D.. 1996. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med. 183:811–820
   PubMed Web of Science ®Google Scholar
• Cleveland, J. L., Dean, M., Rosenberg, N., Wang, J. Y., and Rapp, U. R.. 1989. Tyrosine kinase oncogenes abrogate interleukin-3 dependence of murine myeloid cells through signaling pathways involving c-myc: conditional regulation of c-myc transcription by temperature-sensitive v-abl. Mol. Cell. Biol. 9:5685–5695
   PubMed Web of Science ®Google Scholar
• Cortez, D., Kadlec, L., and Pendergast, A. M.. 1995. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol. Cell. Biol. 15:5531–5541
   PubMed Web of Science ®Google Scholar
• Daley, G. Q., and Baltimore, D.. 1988. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210 bcr/abl protein. Proc. Natl. Acad. Sci. USA 85:9312–9316
   PubMed Web of Science ®Google Scholar
• Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E.. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231–241
   PubMed Web of Science ®Google Scholar
• del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., and Nunez, G.. 1997. Interleukin-3-induced phosphorylation of BAD through the protein kinase akt. Science 278:687–689
   PubMed Web of Science ®Google Scholar
• Dickens, M., Rogers, J. S., Cavanagh, J., Raitano, A., Xia, Z., Halpern, J., Greenberg, M. E., Sawyers, C. L., and Davis, R. J.. 1997. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277:693–696
   PubMed Web of Science ®Google Scholar
• Evans, C. A., Owen-Lynch, P. J., Whetton, A. D., and Dive, C.. 1993. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res. 53:1735–1738
   PubMed Web of Science ®Google Scholar
• Frost, J. A., Geppert, T. D., Cobb, M. H., and Feramisco, J. R.. 1994. A requirement for extracellular signal-regulated kinase (ERK) function in the activation of AP-1 by Ha-Ras, phorbol 12-myristate 13-acetate, and serum. Proc. Natl. Acad. Sci. USA 91:3844–3848
   PubMed Web of Science ®Google Scholar
• Gajewski, T. F., and Thompson, C. B.. 1996. Apoptosis meets signal transduction: elimination of a BAD influence. Cell 87:589–592
   PubMed Web of Science ®Google Scholar
• Goga, A., McLaughlin, J., Afar, D. E., Saffran, D. C., and Witte, O. N.. 1995. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 82:981–988
   PubMed Web of Science ®Google Scholar
• Gross, A., McDonnell, J. M., and Korsmeyer, S. J.. 1999. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1899–1911
   PubMed Web of Science ®Google Scholar
• Harada, H., Becknell, B., Wilm, M., Mann, M., Huang, L. J., Taylor, S. S., Scott, J. D., and Korsmeyer, S. J.. 1999. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol. Cell 3:413–422
   PubMed Web of Science ®Google Scholar
• Hariharan, I. K., Adams, J. M., and Cory, S.. 1988. bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia. Oncogene Res. 3:387–399
   PubMedGoogle Scholar
• Ilaria, R. L., and van Etten, R. A.. 1996. P210 and P190 BCR/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271:31704–31710
   PubMed Web of Science ®Google Scholar
• Kabarowski, J. H., Allen, P. B., and Wiedemann, L. M.. 1994. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J. 13:5887–5895
   PubMed Web of Science ®Google Scholar
• Kelekar, A., Chang, B. S., Harlan, J. E., Fesik, S. W., and Thompson, C. B.. 1997. Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-xL. Mol. Cell. Biol. 17:7040–7046
   PubMed Web of Science ®Google Scholar
• Kurzrock, R., Gutterman, J. U., and Talpaz, M.. 1988. The molecular genetics of Philadelphia chromosome positive leukemias. N. Engl. J. Med. 319:990–998
   PubMed Web of Science ®Google Scholar
• Majewski, M., Nieborowska-Skorska, M., Salomoni, P., Slupianek, A., Reiss, K., Trotta, R., Calabretta, B., and Skorski, T.. 1999. Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res. 59:2815–2819
   PubMed Web of Science ®Google Scholar
• Mandanas, R. A., Leibowitz, D. S., Gharenbaghi, K., Tauchi, T., Burgess, G. S., Miyazawa, K., Jayaram, H. N., and Boswell, H. S.. 1993. Role of p21 Ras in p210 bcr-abl transformation of murine myeloid cells. Blood 82:1838–1847
   PubMed Web of Science ®Google Scholar
• McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K. M., Green, D. R., and Cotter, T. G.. 1994. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83:1179–1187
   PubMed Web of Science ®Google Scholar
• McGahon, A. J., Nishioka, W. K., Martin, S. J., Mahboubi, A., Cotter, T. G., and Green, D. R.. 1995. Regulation of the Fas apoptotic cell death pathway by Abl. J. Biol. Chem. 270:22625–22631
   PubMed Web of Science ®Google Scholar
• Nishii, K., Kabarowski, J. H., Gibbons, D. L., Griffiths, S. D., Titley, I., Wiedemann, L. M., and Greaves, M. F.. 1996. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene 13:2225–2234
   PubMed Web of Science ®Google Scholar
• Okuda, K., Matulonis, U., Salgia, R., Kanakura, Y., Druker, B., and Griffin, J. D.. 1994. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp. Hematol. 22:1111–1117
   PubMed Web of Science ®Google Scholar
• Pendergast, A. M., Quilliam, L. A., Cripe, L. D., Bassing, C. H., Dai, Z., Li, N., Batzer, A., Rabun, K. M., Der, C. J., Schlessinger, J., and Gishizky, M. L.. 1993. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175–185
   PubMed Web of Science ®Google Scholar
• Philpott, K. L., McCarthy, M. J., Klippel, A., and Rubin, L. L.. 1997. Activated phosphatidylinositol 3-kinase and Akt kinase promote survival of superior cervical neurons. J. Cell Biol. 139:809–815
   PubMed Web of Science ®Google Scholar
• Qiu, R. G., Chen, J., Kirn, D., McCormick, F., and Symons, M.. 1995. An essential role for Rac in Ras transformation. Nature 374:457–459
   PubMed Web of Science ®Google Scholar
• Raitano, A., Whang, Y. E., and Sawyers, C. L.. 1997. Signal transduction by wild-type and leukemogenic Abl proteins. Biochim. Biophys. Acta 1333:F201–F216
   PubMed Web of Science ®Google Scholar
• Raitano, A. B., Halpern, J. R., Hambuch, T. M., and Sawyers, C. L.. 1995. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc. Natl. Acad. Sci. USA 92:11746–11750
   PubMed Web of Science ®Google Scholar
• Sambrook, J., Fritsch, E. F., and Maniatis, T.. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y
   Google Scholar
• Sanchez-Garcia, I., and Grutz, G.. 1995. Tumorigenic activity of the BCR-ABL oncogene is mediated by BCL2. Proc. Natl. Acad. Sci. USA 92:5287–5291
   PubMed Web of Science ®Google Scholar
• Sawyers, C. L., Callahan, W., and Witte, O. N.. 1992. Dominant negative myc blocks transformation by ABL oncogenes. Cell 70:901–910
   PubMed Web of Science ®Google Scholar
• Sawyers, C. L., McLaughlin, J., and Witte, O. N.. 1995. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J. Exp. Med. 181:307–313
   PubMed Web of Science ®Google Scholar
• Scheid, M. P., and Duronio, V.. 1998. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. Proc. Natl. Acad. Sci. USA 95:7439–7444
   PubMed Web of Science ®Google Scholar
• Shuai, K., Halpern, J., ten Hoeve, J., Rao, X., and Sawyers, C. L.. 1996. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13:247–254
   PubMed Web of Science ®Google Scholar
• Skorski, T., Bellacosa, A., Nieborowska-Skorska, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., Wasik, M. A., Tsichlis, P. N., and Calabretta, B.. 1997. Transformation of hematopoietic cells by BCR/ABL requires activation of a P1-3k/Akt-dependent pathway. EMBO J. 16:6151–6161
   PubMed Web of Science ®Google Scholar
• Skorski, T., Kanakaraj, P., Neiborowska-Skorska, M., Ratajczak, M. Z., Wen, S. C., Zon, G., Gerrwitz, A. M., Perussia, P., and Calabretta, B.. 1995. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 2:726–736
   Google Scholar
• Skorski, T., Nieborowska-Skorska, M., Szczylik, C., Kanakaraj, P., Perrotti, D., Zon, G., Gerwirtz, A., Perussia, B., and Calabretta, B.. 1995. C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res. 55:2275–2278
   PubMed Web of Science ®Google Scholar
• Songyang, Z., Baltimore, D., Cantley, L. C., Kaplan, D. R., and Franke, T. F.. 1997. Interleukin 3-dependent survival by the Akt protein kinase. Proc. Natl. Acad. Sci. USA 94:11345–11350
   PubMed Web of Science ®Google Scholar
• Wang, H. G., Rapp, U. R., and Reed, J. C.. 1996. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87:629–638
   PubMed Web of Science ®Google Scholar
• Yang, E., Zha, J., Jockel, J., Boise, L. H., Thompson, C. B., and Korsmeyer, S. J.. 1995. Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces Bax and promotes cell death. Cell 80:285–291
   PubMed Web of Science ®Google Scholar
• Zha, J., Harada, H., Osaipov, K., Jockel, J., Waksman, G., and Korsmeyer, S. J.. 1997. BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptic activity. J. Biol. Chem. 39:24101–24104
   Google Scholar
• Zha, J., Harada, H., Yang, E., Jockel, J., and Korsmeyer, S. J.. 1996. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87:619–628
   PubMed Web of Science ®Google Scholar